Estradiol Patch Regulatory Status: US, EU, Canada, and UK Approvals Explained

United States: FDA-approved prescription patches

Estradiol is an FDA-approved prescription estrogen. Transdermal forms include once-weekly or twice-weekly patches sold as Climara, Vivelle-Dot, Minivelle and generics [1]. The Climara label lists four indications: moderate to severe vasomotor symptoms, moderate to severe symptoms of vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevention of postmenopausal osteoporosis [1]. For vaginal symptoms alone it says to consider topical vaginal products first; for osteoporosis prevention alone it says to consider non-estrogen medicines first [1]. Climara is applied once weekly and Vivelle-Dot twice weekly [1][3].

What the US labels still warn about

Climara and Vivelle-Dot carry a boxed warning covering endometrial cancer, cardiovascular disorders, probable dementia and breast cancer [1][3]. It says unopposed estrogen raises endometrial cancer risk in a woman with a uterus and that adding a progestogen reduces endometrial hyperplasia risk [1]. It also says only daily oral conjugated estrogens 0.625 mg were studied in the WHI estrogen-alone substudy, so relevance to lower doses, other routes or other estrogen-alone products is not known [1].

The 2025-2026 FDA labeling change

On 2025-11-10 FDA asked makers of menopausal hormone therapy to remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia; to remove endometrial cancer boxed language except keep it on systemic estrogen-alone products; to remove the recommendation to use the lowest effective dose for the shortest time; and to add consideration of starting therapy for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause, plus WHI data for women aged 50 to 59 [4]. On 2026-02-12 FDA approved the first six updated labels: Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva; 29 companies had submitted proposed changes, and the updated-label list did not include oral estradiol tablets or estradiol patches [5][6].

European Union: central and national routes

The European Medicines Agency medicine finder covers centrally authorised medicines. The EMA page says medicines authorised by individual member states through national procedures are found in national registers, and that its website may not list every nationally authorised option [2]. Canadian and UK approval details are not covered here.